Ken Research Stated North America Clinical Trials Market to Reach USD 67.69 Billion as AI Rewrites Drug Development

From conventional site-based studies to AI-enabled, decentralized research ecosystems, comprehensive market analysis maps the next wave of oncology, precision medicine, metabolic disease, and data-driven clinical development.

Delhi, India, July, 2026, Ken Research released its strategic market analysis titled "North America Clinical Trials Market Outlook to 2030," revealing that the market was valued at USD 44.80 billion in 2024, following historical growth from USD 34.62 billion in 2019. The detailed study outlines how the market is projected to reach USD 67.69 billion by 2030, expanding at a CAGR of 7.10%, driven by strong oncology and precision-medicine pipelines, rising pharmaceutical research investment, decentralized trial adoption, AI-enabled study operations, growing cardiometabolic development, and increasing demand for complex laboratory and data-management services.

The 96-page report provides decision-makers with critical intelligence on clinical trial activity, therapeutic revenue pools, sponsor outsourcing, competitive positioning, operational challenges, regulatory developments, and investment opportunities. North America accounted for approximately 39.4% of the global clinical trials market in 2024, supported by around 48,200 active registered trials, the world's deepest sponsor base, extensive CRO capabilities, leading academic medical centres, and a highly developed investigator-site ecosystem.

"North America is entering a more technology-intensive phase of clinical development," said Namit Goel, Research Director at Ken Research. "The next growth cycle will not be determined by trial volume alone. Oncology complexity, metabolic programmes, biomarker testing, decentralized workflows, artificial intelligence, and richer data requirements are increasing the value generated by every active study."

Download the free sample report: https://www.kenresearch.com/sample-report/north-america-clinical-trials-market?utm_source=OpenPR&utm_medium=Referral&utm_campaign=PR

Key Market Dynamics Reshaping the North America Clinical Trials Landscape

The report identifies four key growth drivers that will define market development:

Oncology and Precision Medicine Momentum
Oncology remains the largest therapeutic revenue pool in the North America clinical trials market, accounting for approximately 35.6% of market revenue in 2024. Oncology studies typically require extensive biomarker testing, complex eligibility criteria, molecular diagnostics, imaging, protocol adaptations, and long-term evidence generation, resulting in higher spending per trial than many general-medicine programmes.

The United States pharmaceutical pipeline included hundreds of medicines under development across lung cancer, lymphoma, and other cancer indications. The FDA's Office of Oncologic Diseases also reported 17 novel oncology therapy approvals during 2024, reinforcing long-term demand for oncology-focused CROs, central laboratories, biomarker providers, imaging specialists, patient-recruitment platforms, and specialist investigator networks.

Decentralized and AI-Enabled Trials

The FDA finalized guidance for decentralized clinical trials in September 2024, supporting broader use of telehealth visits, remote data collection, local healthcare providers, home nursing, digital consent, wearable devices, and technology-enabled patient monitoring. These models can reduce travel burdens, expand patient access, and provide sponsors with greater flexibility in protocol execution.

Artificial intelligence is also moving from isolated experiments into strategic study feasibility, protocol optimization, site selection, data management, document preparation, and clinical research associate support. The report notes that 71% of surveyed Association of Clinical Research Organizations members were using AI in strategic study feasibility and data management, while 64% reported using it for protocol optimization.

Public Research Funding and Institutional Depth

The United States clinical research ecosystem is supported by nearly USD 48 billion in annual National Institutes of Health investment. Approximately 82% of the NIH budget is directed toward extramural research, supporting almost 50,000 grants across more than 2,500 universities, hospitals, medical schools, and research institutions.

This funding expands the early research and proof-of-concept pipeline, strengthens access to specialist investigators, and creates partnership opportunities across oncology, neurology, rare diseases, infectious diseases, and translational medicine. It also provides CROs, laboratories, site networks, and research-technology companies with a deep foundation of future commercial programmes.

Higher Revenue per Active Trial

Market growth is increasingly being driven by study complexity and service intensity rather than trial volume alone. Average revenue per active trial increased from approximately USD 0.88 million in 2019 to USD 0.93 million in 2024 and is projected to reach around USD 1.05 million by 2030.

The increase reflects rising demand for biomarker-heavy oncology trials, rare-disease programmes, decentralized study components, central laboratory services, advanced data management, patient-recruitment technology, imaging, and post-approval evidence generation.

Critical Strategic Questions Addressed

For executives navigating this market transformation, the report addresses four pivotal questions:

Get the complete report here: https://www.kenresearch.com/industry-reports/north-america-clinical-trials-market?utm_source=OpenPR&utm_medium=Referral&utm_campaign=PR

Market Entry Timing

The North America clinical trials market is projected to increase from approximately 48,200 active registered trials in 2024 to around 64,580 trials by 2030. Market value is expected to expand faster than trial volume because sponsors are allocating more resources to complex oncology, rare-disease, metabolic, endocrine, and precision-medicine protocols.

The analysis helps organizations determine whether to prioritize full-service clinical development, functional-service partnerships, central laboratory operations, patient recruitment, data management, decentralized trial technology, early-phase capabilities, or therapeutic specialization.

Therapeutic Portfolio Prioritization

Oncology will remain the largest revenue pool, but metabolic and endocrine programmes are expected to deliver some of the strongest acceleration through 2030. Obesity and cardiometabolic outcome studies frequently involve large patient cohorts, extended follow-up periods, laboratory testing, imaging, adherence monitoring, and event-driven endpoints.

Rare-disease, cell-therapy, and gene-therapy studies also create high-value opportunities because they require specialist patient identification,

biospecimen logistics, complex laboratory support, regulatory expertise, and long-term follow-up systems.

Operational and Regulatory Navigation

Clinical trial sponsors and service providers must manage increasingly complex protocols, regulatory requirements, decentralized elements, data-security expectations, patient-diversity goals, and multi-site execution models.

Protocol amendments can create substantial financial and operational pressure. The report notes that the median direct cost of a substantial amendment reached approximately USD 141,000 for Phase II studies and USD 535,000 for Phase III studies.

Organizations with stronger feasibility analytics, regulatory consulting, site activation, contracting, quality assurance, and data-governance capabilities can reduce delays and protect programme economics.

Competitive Positioning

The market includes approximately 180 participants and is moderately concentrated among large global CRO platforms, specialist clinical-service providers, central laboratories, site networks, and technology companies.

The report profiles 10 major companies, including IQVIA, ICON plc, Covance Inc., Charles River Laboratories International, PAREXEL International Corporation, Syneos Health, Medpace Holdings, PRA Health Sciences, Labcorp Drug Development, and Pharmaceutical Product Development.

Companies are evaluated across revenue scale, clinical development breadth, therapeutic specialization, early-phase capabilities, laboratory network depth, decentralized trial capabilities, data and analytics integration, site-network reach, regulatory consulting, and financial resilience.

Critical Clinical Infrastructure and Regulatory Developments

The report highlights several significant developments that will shape market growth:

Decentralized Trial Regulatory Framework

The FDA's final decentralized clinical trial guidance provides greater clarity on remote visits, telehealth, home-based services, local healthcare-provider participation, digital data collection, and investigator oversight.

This framework supports investment in electronic clinical outcome assessments, remote-consent platforms, wearable-device integration, home nursing, direct-to-patient logistics, telemedicine, and remote-monitoring infrastructure.

Expanding Registered Trial Base

ClinicalTrials.gov reported 19,155 recruiting studies operating exclusively in the United States and another 3,120 studies involving both United States and international locations as of May 7, 2026.

This study density improves patient-enrolment optionality, strengthens investigator-network utilization, and supports demand for site activation, monitoring, central laboratory testing, recruitment, data operations, and regulatory support.

Site Activation and Contracting Modernization

Study start-up remains one of the most significant operating bottlenecks across the market. Approximately 77% of surveyed United States sites identified budget and contract negotiations as the leading contributor to start-up delays.

Only 22% of independent sites reported completing average start-up within 30 days, while 38% required between 31 and 60 days. This creates opportunities for technology platforms and service providers that can streamline coverage analysis, contracting, site payments, budget management, and document workflows.

Book a discovery call with our experts: https://www.kenresearch.com/book-a-discovery-call?utm_source=OpenPR&utm_medium=Referral&utm_campaign=PR

AI Governance and Data Integration

AI-enabled clinical trial operations require validated systems, interoperable data environments, documented human oversight, transparent algorithms, and audit-ready processes.

Commercial advantage will increasingly favour providers capable of combining software with regulatory compliance, therapeutic expertise, operational delivery, and secure clinical-data management. Data Management Services are identified as the fastest-growing service category as wearable data, electronic-source integration, remote monitoring, biomarker datasets, and decentralized workflows expand.

Strategic Value for Decision-Makers

"What distinguishes this analysis is its focus on where clinical-trial economics are actually changing," noted Mr. Harsh Saxena, Principal at Ken Research.
"Beyond market sizing, the report examines therapeutic mix, revenue per study, decentralized execution, artificial intelligence, site economics, competitive capabilities, and emerging service profit pools."

The 96-page mandate delivers essential market intelligence for executives and investors, including:

Detailed segmentation analysis by trial phase, including Phase I, Phase II, Phase III, and Phase IV studies

Study-design analysis covering interventional studies, observational studies, and expanded-access programmes

Therapeutic analysis covering oncology, cardiovascular diseases, infectious diseases, neurology, and other indications

Service analysis covering laboratory services, bioanalytical testing, patient recruitment, data management, and other clinical-development services

Sponsor analysis covering pharmaceutical and biopharmaceutical companies, medical-device companies, academic and research institutions, and other organizations

Historical and forecast models covering market value, active registered trials, annual growth, revenue per active trial, and therapeutic revenue concentration from 2019-2030

Competitive benchmarking of 10 major companies across 10 strategic and operational performance parameters

White-space analysis covering decentralized trials, AI-enabled data management, patient recruitment, biomarker services, cardiometabolic programmes, rare diseases, and specialized clinical infrastructure

Go-to-market recommendations covering entry strategy, positioning, pricing gaps, potential partners, investment requirements, risk-return trade-offs, profitability, and execution roadmaps

Primary and secondary research supported by 212 expert interviews across clinical operations, investigator sites, medical monitoring, central laboratories, biomarker services, patient recruitment, and the wider clinical-development value chain.

The report includes 35 chapters, profiles 10 companies, assesses seven segmentation categories, and provides more than 201 detailed sections covering market assessment, competitive intelligence, go-to-market strategy, and demand-side research.

"As North America moves toward more complex and digitally enabled clinical-development models, successful organizations will need more than operational scale," added Harsh Saxena, Principal at Ken Research. "They will require therapeutic depth, integrated data systems, regulatory credibility, trusted investigator relationships, and the ability to improve patient access without compromising evidence quality."

Industry executives seeking access to the complete analysis can contact Ken Research directly or visit: https://www.kenresearch.com/industry-reports/north-america-clinical-trials-market?utm_source=OpenPR&utm_medium=Referral&utm_campaign=PR

Related Reports

https://www.kenresearch.com/industry-reports/europe-clinical-trials-market?utm_source=OpenPR&utm_medium=Referral&utm_campaign=PR

https://www.kenresearch.com/bahrain-clinical-trials-market?utm_source=OpenPR&utm_medium=Referral&utm_campaign=PR

https://www.kenresearch.com/industry-reports/asia-pacific-clinical-trials-market?utm_source=OpenPR&utm_medium=Referral&utm_campaign=PR

https://www.kenresearch.com/global-clinical-trials-market?utm_source=OpenPR&utm_medium=Referral&utm_campaign=PR

Contact:
Ankur Gupta
ankur.gupta@kenresearch.com
+91 9015378249

Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49 Gurgaon, Haryana - 122001, India

Ken Research delivers strategic market intelligence that drives confident decision-making for industry leaders. With specialized expertise in high-growth markets across emerging economies, the firm provides data-driven insights that translate into competitive advantage for global organizations and investors.

This release was published on openPR.